ArticleBMC cancer2025
Identification of the IFN-γ/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous B-cell malignancy influenced by immune dysregulation, posing significant clinical challenges. Lymphocyte subsets (e.g., CD4 + T helper 1/ T helper 2 cells) and their cytokines (IFN-γ/IL-4) are readily measurable immune markers involved in DLBCL pathogenesis and may independently predict prognosis. However, the prognostic value of these two combined clinical laboratory findings in newly diagnosed DLBCL patients remains uninvestigated.
methodHere, we retrospectively analyzed 94 newly diagnosed DLBCL patients treated at our institution between 2017 and 2023. The prognostic influences of lymphocyte subsets, cytokines levels and other factors on progression-free survival (PFS) and overall survival (OS) were studied by Kaplan-Meier analysis and Cox regression (univariate/multivariate). Then we constructed an immune-related prognostic score model (IRPS) and validated it in another independent cohort.
resultsThe results suggested that a high IFN-γ/IL-4 ratio and elevated CD4 + T cell count were favorable risk variables for both PFS and OS in DLBCL patients. Besides, multivariate analysis showed that age was marginally associated with the worse OS whereas low CD8 + T cell count was associated with the inferior PFS. Moreover, elevated pretreatment IFN-γ/IL-4 ratio was significantly correlated with better clinical response efficacy. Compared to those treatment-responsive patients, lower level of IFN-γ/IL-4 ratio was discovered in patients experienced with progression during the subsequent treatment cycles. Additionally, a new immune-related prognostic score model was constructed based on age, CD4 + T cell count and IFN-γ/IL-4 ratio, where high-risk patients had worse overall survival than low-risk patients. Meanwhile, the IRPS could refine the International Prognostic Index (IPI) score well and validation of the IRPS in another independent cohort confirmed its effectiveness.
conclusionIFN-γ/IL-4 ratio is a practical prognostic marker in newly diagnosed DLBCL, and the IRPS model shows potential for predicting PFS and OS in DLBCL, enabling improved risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.